Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07221253 · ClinicalTrials.gov registry record · Phase 3

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

A Phase 3 study of Biliary Tract Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
1,100
Enrollment target
20
Study locations

NCT07221253 is a Phase 3 study of Biliary Tract Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 1,100 participants, above the 209-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (426% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07221253, a Phase 3 study of Biliary Tract Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
1,100 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.

Conditions Studied

Biliary Tract Cancer

Interventions

  • DRUG Rilvegostomig
  • DRUG Durvalumab
  • DRUG Gemcitabine/Cisplatin

Study Locations (20)

California

  • Research Site - Duarte
  • Research Site - Orange
  • Research Site - Santa Monica
  • Research Site - Stanford

Arizona

  • Research Site - Phoenix
  • Research Site - Tucson

Connecticut

  • Research Site - Hartford
  • Research Site - New Haven

District of Columbia

  • Research Site - Washington D.C.
  • Research Site - Washington D.C.

Florida

  • Research Site - Jacksonville
  • Research Site - Jacksonville

Illinois

  • Research Site - Chicago
  • Research Site - Chicago

Alabama

  • Research Site - Birmingham

Colorado

  • Research Site - Aurora

Trial Details

FieldValue
Enrollment Target 1,100 participants
Start Date 2025-12-04
Est. Completion 2029-07-04
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07221253

The ClinicalTrials.gov registry entry for NCT07221253 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 209-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (426% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Biliary Tract Cancer appearing as the primary indexed condition, and to 3 interventions - of which Rilvegostomig is the first listed.

NCT07221253 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Arizona, Connecticut.

Frequently Asked Questions

What is clinical trial NCT07221253 about?

NCT07221253 is a clinical study titled "A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)". The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.

What is the current status of trial NCT07221253?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,100 participants. The study started on 2025-12-04. Estimated completion is 2029-07-04.

What conditions does trial NCT07221253 study?

This clinical trial studies the following conditions: Biliary Tract Cancer.

What interventions are being tested in trial NCT07221253?

The interventions under investigation include: Rilvegostomig (DRUG), Durvalumab (DRUG), Gemcitabine/Cisplatin (DRUG).

Who is sponsoring clinical trial NCT07221253?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07221253 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Biliary Tract Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Biliary Tract Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.